Every round on record, with the sources behind each and the investors on them.
A digital transformation (DX) platform designed to solve the structural issue of 'uneven distribution' within pharmaceutical supply chains
9lione.netNerima Ward, TokyoHealthtechFounded 2018
6 sources · checked 16 times, last 29d ago
Expected; not announced.
Source 2 reports a separate Series A extension exceeding ¥20 million on 2026-09-25; it is not combined with this ¥120 million Series A.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A ext. Series A extension [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts.Expected | $758K ¥120 million | 2026-09-11 | Yokohama Capital | No recent discussion |
6 sources · checked 16 times, last 29d ago Expected; not announced. [ VERIFIED · CORRECTED ] read against 4 of 6 sources
Source 2 reports a separate Series A extension exceeding ¥20 million on 2026-09-25; it is not combined with this ¥120 million Series A. | ||||
9lione builds a cloud medicine-inventory and licensed redistribution platform for hospitals, clinics, pharmacies and other medical institutions, matching surplus drugs with facilities facing shortages.
9lione targets a costly mismatch in which one medical facility has unused drugs while another cannot source them; its latest update says more than 1,200 facilities are registered and annual GMV exceeds ¥2 billion. The ¥120 million Series A and ongoing equity-crowdfunding extension fund nationwide logistics and sales expansion, AI inventory visibility and automated trading, making the bet that licensed redistribution plus demand data can reduce waste and shortages.
Checked against 9 sources on Sep 27
Also named as backers in company research: Incubate Fund, DG Ventures, Mitsui Sumitomo Insurance Capital (MS&AD Ventures), Globe Advisors, Nanobank